Is Now the Time to Buy GlaxoSmithKline plc (GSK)?

Page 2 of 2

Furthermore, GlaxoSmithKline is taking action to cut costs and is targeting yearly cost savings of 1 billion pounds by 2016. In addition, GlaxoSmithKline has a strong product pipeline, and 14 new treatments are expected to be on sale within the next two years.

The company is also seeking acquisitions to bolster organic growth and recently acquired U.S.-based Human Genome Sciences, which I believe should further boost the company’s pipeline and longer-term prospects.

Overall, despite the current challenges, I believe GlaxoSmithKline’s future is looking up, and the company has a solid history of returning cash to shareholders. So all in all, I feel now looks to be a good time to buy GlaxoSmithKline at 1,455 pence.

More FTSE opportunities
As well as GlaxoSmithKline, I am also positive on the FTSE shares highlighted in “8 Dividend Plays Held by Britain’s Super Investor.” This exclusive report reveals the favorite income stocks owned by Neil Woodford — the City legend whose portfolios have thrashed the FTSE All-Share by 200% during the 15 years to October 2012.

In the meantime, please stay tuned for my next verdict on a FTSE 100 share.

The article Is Now the Time to Buy GlaxoSmithKline? originally appeared on Fool.com and is written by Rupert Hargreaves.

Fool contributor Rupert Hargreaves has no position in any stocks mentioned. The Motley Fool recommends GlaxoSmithKline.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Page 2 of 2